Abstract
The review highlights recent reports of advances in quantitative neuroproteomics that use new methods to analyze brain functions. Functional neuroproteomics provides new insight into the mechanisms of brain function and neurodegenerative diseases by identifying expressed proteins and their interactions. Analysis of the brain’s proteome made it possible to establish the key proteins that underlie synaptic dysfunction in Alzheimer’s disease and to substantiate the important mechanisms for prognostic and diagnostic biomarkers of the disease.
Similar content being viewed by others
REFERENCES
Adav, S.S., Park, J.E., and Sze, S.K., Quantitative profiling brain proteomes revealed mitochondrial dysfunction in Alzheimer’s disease, Mol. Brain, 2019, vol. 12, no. 1, p. 8.
Agoston, D.V. and Elsayed, M., Serum-based protein biomarkers in blast-induced traumatic brain injury spectrum disorder, Front. Neurol., 2012, vol. 3, p. 107.
Archakov, A.I., What’s behind genomics? Proteomics, Vopr. Med. Khim., 2000, vol. 46, no. 4, pp. 335–343.
Bastos, P., Ferreira, R., Manadas, B., et al., Insights into the human brain proteome: disclosing the biological meaning of protein in networks cerebrospinal fluid, Crit. Rev. Clin. Lab. Sci., 2017, vol. 54, no. 3, pp. 185–204.
Bateman, R.J., Xiong, C., Benzinger, T.L., et al., Clinical and biomarker changes in dominantly inherited Alzheimer’s disease, N. Eng. J. Med., 2012, vol. 367, pp. 795–804.
Bayes, A. and Grant, S.G., Neuroproteomics: understanding the molecular organization and complexity of the brain, Nat. Rev. Neurosci., 2009, vol. 10, no. 9, pp. 635–646.
Bereczki, E., Francis, P.T., Howlett, D., et al., Synaptic proteins predict cognitive decline in Alzheimer’s disease and Lewy body dementia, Alzheimer’s Dementia, 2016, vol. 12, pp. 1149–1158.
Bereczki, E., Branca, R.M., Francis, P.T., et al., Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach, Brain, 2018, vol. 141, no. 2, pp. 582–595.
Blackstock, W.P. and Weir, M.P., Proteomics: quantitative and physical mapping of cellular proteins, Trends Biotechnol., 1999, vol. 17, pp. 121–127.
Carrillo, M.C., Dean, R.A., Devous, M.D.S., et al., Revolutionizing Alzheimer’s disease and clinical trials through biomarkers, Alzheimer’s Dementia, 2015, vol. 1, pp. 412–419.
Casaletto, K.B., Elahi, F.M., Bettcher, B.M., et al., Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers, Neurology, 2017, vol. 89, no. 17, pp. 1782–1788.
Chiasserini, D., van Weering, J.R.T., Piersma, S.R., et al., Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset, J. Proteomics, 2014, vol. 106, pp. 191–204.
Chick, J.M., Kolippakkam, D., Nusinow, D.P., et al., A mass-tolerant database search identifies a large proportion of unassigned spectra in shotgun proteomics as modified peptides, Nat. Biotechnol., 2015, vol. 33, pp. 743–749.
Collins, M.O., Yu, L., Coba, M.P., et al., Proteomic analysis of in vivo phosphorylated synaptic proteins, J. Biol. Chem., 2005, vol. 280, pp. 5972–5982.
Coughenour, H.D., Spaulding, R.S., and Thompson, C.M., The synaptic vesicle proteome: a comparative study in membrane protein identification, Proteomics, 2004, vol. 4, pp. 3141–3155.
Craft, G.E., Chen, A., and Nairn, A.C., Recent advances in quantitative neuroproteomics, Methods, 2013, vol. 61, no. 3, pp. 186–218.
Cuadrado, E., Rosell, A., Penalba, A., et al., Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study, J. Proteome Res., 2009, vol. 8, no. 6, pp. 3191–3197.
Curran, S., McKay, J.A., McLeod, H.L., and Murray, G.I., Laser capture microscopy, Mol. Pathol., 2000, vol. 53, pp. 64–68.
DeKosky, S.T. and Scheff, S.W., Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity, Ann. Neurol., 1990, vol. 27, pp. 457–464.
Del Campo, M., Mollenhauer, B., Bertolotto, A., et al., Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update, Biomarkers Med., 2012, vol. 6, pp. 419–430.
Dubois, B., Hampel, H., Feldman, H.H., et al., Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria, Alzheimer’s Dementia, 2016, vol. 12, pp. 292–323.
Duits, F.H., Brinkmalm, G., Teunissen, C.E., et al., Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease, Alzheimer’s Res. Ther., 2018, vol. 10, no. 1, p. 5.
Frank, R.A. and Grant, S.G., Supramolecular organization of NMDA receptors and the postsynaptic density, Curr. Opin. Neurobiol., 2017, vol. 45, pp. 139–147.
Gajera, C.R., Fernandez, R., Postupna, N., et al., Mass synaptometry: high-dimensional multi parametric assay for single synapses, J. Neurosci. Methods, 2019, vol. 312, pp. 73–83.
Gomazkov, O.A., Why neuropeptides are universal regulators? Priroda (Moscow), 1999, no. 3, pp. 3–13.
Guan, J.S., Su, S.C., Gao, J. et al. Cdk5 is required for memory function and hippocampal plasticity via the cAMP signaling pathway, PLoS One, 2011, vol. 6, no. 9, p. e25735.
He, X.Y., Dan, Q.Q., Wang, F., et al., Protein network analysis of the serum and their functional implication in patients subjected to traumatic brain injury, Front. Neurosci., 2019, vol. 12, p. 1049.
Hedl, T.J., San Gil, R., Cheng, F., et al., Proteomics approaches for biomarker and drug target discovery in ALS and FTD, Front. Neurosci., 2019, vol. 13, p. 548.
Higginbotham, L., Dammer, E.B., Duong, D.M., et al., Network analysis of a membrane-enriched brain proteome across stages of Alzheimer’s disease, Proteomes, 2019, vol. 7, no. 3, p. e30.
Hondius, D.C., van Nierop, P., Li, K.W., et al., Profiling the human hippocampal proteome at all pathologic stages of Alzheimer’s disease, Alzheimer’s Dementia, 2016, vol. 12, pp. 654–668.
Hu, Y., Malone, J.P., Fagan, A.M., et al., Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid, Mol. Cell. Proteomics, 2005, vol. 4, no. 12, pp., 2000–2009.
Ibáñez, C., Cifuentes, A., and Simó, C., Recent advances and applications of metabolomics to investigate neurodegenerative diseases, Int. Rev. Neurobiol., 2015, vol. 122, pp. 95–132.
Jack, C.R., Knopman, D.S., Jagust, W.J., et al., Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade, Lancet Neurol., 2010, vol. 9, pp. 119–128.
Johnson, E.C.B., Dammer, E.B., Duong, D.M., et al., Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease, Mol. Neurodegener., 2018, vol. 13, no. 1, p. 52.
Kim, M.S., Pinto, S.M., Getnet, D., et al., A draft map of the human proteome, Nature, 2014, vol. 509, no. 7502, pp. 575–581.
Kirvell, S.L., Esiri, M., and Francis, P.T., Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer’s disease, J. Neurochem., 2006, vol. 98, pp. 939–950.
Klein, H.U., Bennett, D.A., and De Jager, P.L., The epigenome in Alzheimer’s disease: current state and approaches for a new path to gene discovery and understanding disease mechanism, Acta Neuropathol., 2016, vol. 132, pp. 503–514.
Koshtoyants, Kh.S., Belkovye tela, obmen veshchestv i nervnaya regulyatsiya (Protein Bodies, Metabolism, and Nervous Regulation), Moscow: Akad. Nauk SSSR, 1951.
Lachén-Montes, M., González-Morales, A., Fernández-Irigoyen, J., and Santamaría, E., Determination of cerebrospinal fluid proteome variations by isobaric labeling coupled with strong cation-exchange chromatography and tandem mass spectrometry, Methods Mol. Biol., 2019, vol. 2044, pp. 155–168.
Lamond, A.I., Uhlen, M., Horning, S., et al., Advancing cell biology through proteomics in space and time, Mol. Cell. Proteomics., 2012, vol. 11, no. 3, p. O112.017731.
Leverenz, J.B., Umar, I., Wang, Q., et al., Proteomic identification of novel proteins in cortical Lewy bodies, Brain Pathol., 2007, vol. 17, no. 2, pp. 139–145.
Li, K.W., Ganz, A.B., and Smit, A.B., Proteomics of neurodegenerative diseases: analysis of human post-mortem brain, J. Neurochem., 2019, vol. 151, no. 4, pp. 435–445.
Lleó, A., Núñez-Llaves, R., Alcolea, D., et al., Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid, Mol. Cell Proteomics, 2019, vol. 18, no. 3, pp. 546–560.
Macron, C., Lane, L., Núñez Galindo, A., and Dayon, L., Deep dive on the proteome of human cerebrospinal fluid: a valuable data resource for biomarker discovery and missing protein identification, J. Proteome Res., 2018, vol. 17, no. 12, pp. 4113–4126.
Masliah, E., Mallory, M., Alford, M., et al., Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease, Neurology, 2001, vol. 56, pp. 127–129.
Mendonça, C.F., Kuras, M., Nogueira, F.C.S., et al., Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer’s disease, Neurobiol. Dis., 2019, vol. 130, p. e104509.
Morciano, M., Burre, J., Corvey, C., et al., Immunoisolation of two synaptic vesicle pools from synaptosomes: a proteomics analysis, J. Neurochem., 2005, vol. 95, pp. 1732–1745.
Moya-Alvarado, G., Gershoni-Emek, N., Perlson, E., and Bronfman, F.C., Neurodegeneration and Alzheimer’s disease. What can proteomics tell us about the Alzheimer’s brain?, Mol. Cell Proteomics, 2016, vol. 15, pp. 409–425.
Natividad, L.A., Buczynski, M.W., McClatchy, D.B., and Yates, J.R., From synapse to function: a perspective on the role of neuroproteomics in elucidating mechanisms of drug addiction, Proteomes, 2018, vol. 6, no. 4, p. e50.
Núñez Galindo, A., Macron, C., Cominetti, O., and Dayon, L., Analyzing cerebrospinal fluid proteomes to characterize central nervous system disorders: a highly automated mass spectrometry-based pipeline for biomarker discovery, Methods Mol. Biol., 2019, vol. 1959, pp. 89–112.
Olsen, J.V., Nielsen, P.A., Andersen, J.R., et al., Quantitative proteomic profiling of membrane proteins from the mouse brain cortex, hippocampus, and cerebellum using the HysTag reagent: mapping of neurotransmitter receptors and ion channels, Brain Res., 2007, vol. 1134, no. 1, pp. 95–106.
Otto, M., Bowser, R., Turner, M., et al., Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS, Amyotrophic Lateral Scler., 2012, vol. 13, pp. 1–10.
Perrin, R.J., Payton, J.E., Malone, J.P., et al., Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation, PLoS One, 2013, vol. 8, no. 5, p. e64314.
Reiber, H., Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics, Restor. Neurol. Neurosci., 2003, vol. 21, nos. 3–4, pp. 79–96.
Rockenstein, E., Nuber, S., Overk, C.R., et al., Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo, Brain, 2014, vol. 137, no. 5, pp. 1496–1513.
Scheff, S.W., Price, D.A., Schmitt, F.A., et al., Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment, Neurology, 2007, vol. 68, pp. 1501–1508.
Schilde, L.M., Kösters, S., Steinbach, S., et al., Protein variability in cerebrospinal fluid and its possible implications for neurological protein biomarker research, PLoS One, 2018, vol. 13, no. 11, p. e0206478.
Seyfried, N.T., Dammer, E.B., Swarup, V., and Nandakumar, D., A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer’s disease, Cell Syst., 2017, vol. 4, no. 1, pp. 60–72.
Shevchenko, G., Konzer, A., Musunuri, S., and Bergquist, J., Neuroproteomics tools in clinical practice, J. Biochim. Biophys. Acta, 2015, vol. 1854, no. 7, pp. 705–717.
Spector, R., Snodgrass, R.S., and Johanson, C.E., A balanced view of the cerebrospinal fluid composition and functions: focus on adult humans, Exper. Neurol., 2015, vol. 273, pp. 57–68.
Sultana, R., Perluigi, M., and Butterfield, D.A., Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer’s disease: insights into mechanism of neurodegeneration from redox proteomics, Antioxid. Redox Signaling, 2006, vol. 8, pp. 2021–2037.
Takamori, S., Holt, M., Stenius, K., et al., Molecular anatomy of a trafficking organelle, Cell, 2006, vol. 127, pp. 831–846.
Terry, R.D., Masliah, E., Salmon, D.P., et al., Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment, Ann. Neurol., 1991, vol. 30, pp. 572–580.
Teunissen, C.E., Petzold, A., Bennett, J.L., et al., A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking, Neurology, 2009, vol. 73, pp. 1914–1922.
Trinidad, J.C., Thalhammer, A., Specht, C.G., et al., Quantitative analysis of synaptic phosphorylation and protein expression, Mol. Cell Proteomics, 2008, vol. 7, no. 4, pp. 684–696.
Verstraeten, A., Theuns, J., and van Broeckhoven, C., Progress in unraveling the genetic etiology of Parkinson disease in a genomic era, Trends Genet., 2015, vol. 31, pp. 140–149.
Wang, Q., Woltjer, R.L., Cimino, P.J., et al., Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein, FASEB J., 2005, vol. 19, no. 7, pp. 869–871.
Wasinger, V.C., Cordwell, S.J., Cerpa-Poljak, A., et al., Progress with gene-product mapping of the Mollicutes: mycoplasma genitalium, Electrophoresis., 1995, vol. 7, pp. 1090–1094.
Westwood, S., Baird, A.L., Anand, S.N., et al., Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer’s disease multimodal biomarker discovery cohort, J. Alzheimer’s Dis., 2020, vol. 74, pp. 213–225.
Wilkins, M. Proteomics data mining, Exp. Rev. Proteomics, 2009, vol. 6, no. 6, pp. 599–603.
Wilson, R.S. and Nairn, A.C., Cell-type-specific proteomics: a neuroscience perspective, Proteomes, 2018, vol. 6, no. 4, p. e51.
Wingo, A.P., Dammer, E.B., Breen, M.S., et al., Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age, Nat. Commun., 2019, vol. 10, no. 1, p. 1619.
Xiong, X.G., Liang, Q., Zhang, C., et al., Serum proteome alterations in patients with cognitive impairment after traumatic brain injury revealed by iTRAQ-based quantitative proteomics, Biomed. Res. Int., 2017, vol. 2017, art. ID 8572509.
Zhang, Q., Ma, C., Gearing, M., and Wang, P.G., Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer’s disease, Acta Neuropathol. Commun., 2018, vol. 6, no. 1, art. ID 19.
Zhu, H., Tamura, T., and Hamachi, I., Chemical proteomics for subcellular proteome analysis, Curr. Opin. Chem. Biol., 2019, vol. 48, pp. 1–7.
ACKNOWLEDGMENTS
The author would like to thank Prof. N.A. Krupina and Prof. V.G. Zgoda for their valuable comments and support of this article.
Funding
The work was carried out within the framework of the Russian State Academies of Sciences Fundamental Research Program for 2013–2020.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests. The authors declare that they have no conflicts of interest.
Statement on the welfare of humans or animals. This article does not contain any studies involving animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Gomazkov, O.A. Neuroproteomics: How a Multitude of Proteins Reflect Brain Functions. Biol Bull Rev 11, 143–153 (2021). https://doi.org/10.1134/S2079086421020043
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S2079086421020043